Elevated serum uric acid level was a notable adverse event during combination therapy with sofosbuvir and ribavirin

Publisher： John Wiley & Sons Inc

E-ISSN： 1872-034x|48|3|E347-E353

ISSN： 1386-6346

Source： HEPATOLOGY RESEARCH, Vol.48, Iss.3, 2018-02, pp. : E347-E353

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

EFFECT OF SHORT‐TERM ORAL RNA THERAPY ON THE SERUM URIC ACID LEVEL AND MEMORY FUNCTION IN SENILE VERSUS SENESCENT SUBJECTS

By  

JOURNAL OF AMERICAN GERIATRICS SOCIETY, Vol. 15, Iss. 4, 1967-04 ,pp. : 364-372

John Wiley & Sons Inc

Access to resources Recommend Favorite

Temporal dynamics of inflammatory cytokines/chemokines during sofosbuvir and ribavirin therapy for genotype 2 and 3 hepatitis C infection

By  

HEPATOLOGY, Vol. 270-9139, Iss. 4, 2015-10 ,pp. : 1047-1058

John Wiley & Sons Inc

Access to resources Recommend Favorite

Temporal dynamics of inflammatory cytokines/chemokines during sofosbuvir and ribavirin therapy for genotype 2 and 3 hepatitis C infection

By  

HEPATOLOGY, Vol. 62, Iss. 4, 2015-10 ,pp. : 1047-1058

John Wiley & Sons Inc

Access to resources Recommend Favorite

Significance of Serum Ribavirin Concentration in Combination Therapy of Interferon and Ribavirin for Chronic Hepatitis C

By  

Intervirology, Vol. 48, Iss. 2-3, 2005-03 ,pp. : 138-144

Karger

Access to resources Recommend Favorite

Eicosapentaenoic Acid Could Permit Maintenance of the Original Ribavirin Dose in Chronic Hepatitis C Virus Patients during the First 12 Weeks of Combination Therapy with Pegylated Interferon-α and Ribavirin

By  

Intervirology, Vol. 50, Iss. 6, 2008-02 ,pp. : 439-446

Karger

Access to resources Recommend Favorite